(Q36788512)

English

Development of histone deacetylase inhibitors for cancer treatment

scientific article published on April 2007

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

1 reference

Europe PubMed Central

Development of histone deacetylase inhibitors for cancer treatment (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

author name string

Douglas Marchion

1

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Pamela Münster

2

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

publication date

1 April 2007

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Expert Review of Anticancer Therapy

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

583-598

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Chromatin modifier enzymes, the histone code and cancer

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Cancer genes and the pathways they control

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

ACETYLATION AND METHYLATION OF HISTONES AND THEIR POSSIBLE ROLE IN THE REGULATION OF RNA SYNTHESIS

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone acetylation in chromatin structure and transcription

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

DNA methylation patterns and epigenetic memory

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Gene silencing in cancer in association with promoter hypermethylation

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Worms gang up on bacteria

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Mammalian chromodomain proteins: their role in genome organisation and expression

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy?

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Sirtuins in aging and age-related disease.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

The Sir 2 family of protein deacetylases

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Diversity in the Sir2 family of protein deacetylases

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase inhibitors in cancer treatment

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylases and cancer: causes and therapies

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Inhibitors of histone deacetylase as new anticancer agents

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase inhibitors: from target to clinical trials

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone Deacetylase Inhibitors: From Chromatin Remodeling to Experimental Cancer Therapeutics

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Prospects: histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Expression profile of histone deacetylase 1 in gastric cancer tissues.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

ICI182,780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor alpha from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Anticancer activities of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase inhibitors: insights into mechanisms of lethality

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Valproic acid alters chromatin structure by regulation of chromatin modulation proteins

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Genes modulated by histone acetylation as new effectors of butyrate activity

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

SU5416 delays wound healing through inhibition of TGF-beta 1 activation

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Effectiveness of trichostatin A as a potential candidate for anticancer therapy in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Sodium valproate induces apoptosis in the rat hepatoma cell line, FaO.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase interacts directly with DNA topoisomerase II

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Activation of mitochondrial pathway is crucial for tumor selective induction of apoptosis by LAQ824.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, a

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Trichostatin A induces apoptosis in lung cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway?

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

The ABCs of SMC proteins: two-armed ATPases for chromosome condensation, cohesion, and repair

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

RITS acts in cis to promote RNA interference-mediated transcriptional and post-transcriptional silencing

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Inhibition of IL-8 gene expression in Caco-2 cells by compounds which induce histone hyperacetylation

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Regulation of microglial inflammatory response by histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

FR901228, an inhibitor of histone deacetylases, increases the cellular responsiveness to IL-6 type cytokines by enhancing the expression of receptor proteins

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Acetylation: a regulatory modification to rival phosphorylation?

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

The diversity of acetylated proteins

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Stat3 dimerization regulated by reversible acetylation of a single lysine residue

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Regulation of E2F1 activity by acetylation

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Acetylation of the p53 DNA-binding domain regulates apoptosis induction

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Acetylation of Stat1 modulates NF-kappaB activity

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

A specific lysine in c-Jun is required for transcriptional repression by E1A and is acetylated by p300

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Acetylation and deacetylation of non-histone proteins

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Effect of all-trans retinoic acid and sodium butyrate in vitro and in vivo on thyroid carcinoma xenografts

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Sensitization to UV-induced apoptosis by the histone deacetylase inhibitor trichostatin A (TSA).

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Bmf contributes to histone deacetylase inhibitor-mediated enhancing effects on apoptosis after ionizing radiation

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

The leukemia-associated transcription repressor AML1/MDS1/EVI1 requires CtBP to induce abnormal growth and differentiation of murine hematopoietic cells

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Role of the histone deacetylase complex in acute promyelocytic leukaemia

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase is a target of valproic acid-mediated cellular differentiation

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

A common mechanism of action for three mood-stabilizing drugs

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase activity is required for full transcriptional repression by mSin3A

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/kiaa0071 and Mta-L1

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

CoREST is an integral component of the CoREST- human histone deacetylase complex

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase 1: a target of 9-hydroxystearic acid in the inhibition of cell growth in human colon cancer.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase 1 is required for cell cycle exit and differentiation in the zebrafish retina

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

A dynamic role for HDAC7 in MEF2-mediated muscle differentiation.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Differential localization of HDAC4 orchestrates muscle differentiation

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

HDAC6 is a microtubule-associated deacetylase

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Identification of novel isoform-selective inhibitors within class I histone deacetylases

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Cell cycle behavior of human HP1 subtypes: distinct molecular domains of HP1 are required for their centromeric localization during interphase and metaphase

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.583

21 January 2018

The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1124/MOL.105.017145

Identifiers

10.1586/14737140.7.4.583

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36788512&oldid=2155364561"